期刊文献+

有限采样法估算霉酚酸药-时曲线下面积 被引量:12

Limited Sampling Strategy for Estimating the Area Under Concentration-Time Curve of Mycophenolic Acid
原文传递
导出
摘要 目的建立有限采样法估算霉酚酸药-时曲线下面积的模型。方法10例肾移植患者服用霉酚酸500mg,bid,达稳态后测定服药前和服药后0.25,0.5,1,1.5,2,3,4,6,8,10和12h的浓度,用SPSS软件采用多元线性回归分别拟合单个或2~4个采血点拟合有限采样法估算MPA曲线下面积的回归方程及相关系数。结果单点拟合的复相关系数均较低,2~4点拟合明显优于单点拟合,其中0,6,8和0,1,63点拟合的回归方程与实测AUC0~12的相关性较好,其复相关系数分别为0.961和0.943,两者平均估计误差分别为(0.91±8.59)%和(-14.38~6.59)%,绝对估计误差分别为(6.92±4.64)%和(1.13~27.54)%。结论本实验拟合的3点预测MPAAUC简化计算公式能较好地反映MPA药-时曲线下面积,适合应用于环孢素与MMF合用的中国肾移植受者的MPA治疗药物监测。 OBJECTIVE To establish a limited sampling strategy (LSS) model for estimating the area under the concentration-time curve of mycophenolic acid. METHODS 10 Renal allograft recipients were treated with MMF 500 mg bid.Plasma MPA concentrations were measured at pre-dose, 0.25, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 10 and 12 h after dosage. The correlation between AUC and one or 2 to 4 concentration points were established using multiple liner regression by SPSS. RESULTS Single point was badly correlated with detected AUC. Abbreviated MPA model equations based on 0, 6, 8 h or 0, 1,6 h three sampling times were fitted to MPA AUC0-12, with good correlation coefficients of 0.961 and 0.943 respectively. The mean prediction errors were (0.91±8.59) % and (-14.38-6.59) % respectively, the absolute prediction errors were (6.92±4.64) % and (1.13-27.54) % respectively. CONCLUSION The abbreviated model equations established in this study can well reflect MPA AUC, and it is recommend for MPA therapeutic drug monitoring in Chinese patients treated with cyclosporine combinated with MMF.
出处 《中国药学杂志》 CAS CSCD 北大核心 2009年第8期611-614,共4页 Chinese Pharmaceutical Journal
基金 广州市属高校科技项目(61027) 广东省医院药学研究基金(2008018)
关键词 霉酚酸 有限采样法 药动学 mycophenolic acid limited sampling strategy pharmacokinetics
  • 相关文献

参考文献10

  • 1STAATZ C E, TETT S E. Clinical pharmacokinetics and pharmacodynamics of mycophenolate in solid organ transplant recipients[J]. Clin Pharmacokinet, 2007, 46(1): 13-58.
  • 2WESTLEY I S, BROGAN L R, MORRIS R G, et al. Role of Mrp2 in the hepatic disposition of mycophenolic acid and its glucuronide metabolites: effect ofcyclosporine[J]. Drug Metab Dispos, 2006, 34(2): 261-266.
  • 3GUIDO F. Abbreviated mycophenolic acid AUC from CO, C1, C2, and C4 is preferable in children after renal transplantation on mycophenolate mofetil and tacrolimus therapy[J]. Transpl Int, 2004, 17 (3) : 120-125.
  • 4周佩军,徐达,王祥慧,余自成,赵菊平.肾移植受者霉酚酸治疗药物监测[J].上海交通大学学报(医学版),2006,26(6):680-684. 被引量:11
  • 5FATELA C D, HINOJOSA P R, PERALVO R, et al. Pharmacokinetic evaluation of mycophenolic acid profiles during the period immediately following an orthotopic liver transplant[J]. Transplant Proc, 2006, 38(8): 2482-2485.
  • 6JIAO Z, ZHONG J Y, ZHANG M, et al. Total and free mycophenolic acid and its 7-O-glucuronide metabolite in Chinese adult renal transplant patients: pharmacokinetics and application of limitedsamplingstrategies[J].Eur J Clin Pharmacol, 2007, 63(2): 27-37.
  • 7TING L S, PARTOVI N, LEVY R D, et al. Limited sampling strategy for predicting area under the concentration-time curve of mycophenolic acid in adult lung transplant recipients[J]. Pharmacotherapy, 2006, 26(9): 1232-1240.
  • 8石茹,文爱东,赵磊,林琳,王萌,吴寅.HPLC法测定肾脏移植患者血浆中霉酚酸浓度及其药代动力学[J].第四军医大学学报,2004,25(15):1416-1418. 被引量:13
  • 9VAN GELDER T, LE MEUR Y, SHAW L M.Therapeutic drug monitoring of mycophenolate mofetil in transplantation[J]. Ther Drug Monit, 2006, 28(2): 145-154.
  • 10丁俊杰,焦正,李中东,施孝金,钟明康.有限采样法估算口服托烷司琼药时曲线下面积模型的建立和验证[J].复旦学报(医学版),2006,33(6):770-775. 被引量:4

二级参考文献39

  • 1丁俊杰,焦正,李中东,施孝金,钟明康,王宏图.有限抽样法估算健康志愿者口服环孢素A的药时曲线下面积[J].中国临床药理学杂志,2005,21(2):154-157. 被引量:5
  • 2焦正,蒋新国,钟明康,陆伟跃.药物临床研究的计算机模拟[J].中国新药与临床杂志,2005,24(6):491-496. 被引量:13
  • 3徐红蓉,李雪宁,陈伟力.单剂口服盐酸托烷司琼颗粒剂在健康人体的生物等效性[J].中国临床药理学杂志,2005,21(3):194-197. 被引量:5
  • 4Meisser BM, Pfeiffer M, Jagiello-Kraatz M, et al. Mycophenolate mofetil dose adjustments based on trough levels improve outcome after heart transplantation significantly[J]. J Heart Lung Transplant,1998; 17(1):85-88.
  • 5Sanquer S, Breil M, Baron C, et al. Trough blood concentrations in long-term treatment with mycophenolate mofeti[J]. Lancet,1998;351(9115):1557-1561.
  • 6Jones CE, Taylor PJ, Johnson AG, et al. High-performance liquid chromatography determination of mycophenolic acid and its glucuronide metabolite in human plasma[J]. J Chromatogr B Biomed Sci Appl, 1998; 708(1): 229-233.
  • 7Na-Bangchang K, Supasyndh O, Supaporn T, et al. Simple and sensitive high-performance liquid chromatographic method for the determination of mycophenolic acid in plasma[J]. J Chromatogr B Biomed Sci Appl, 2000;738(1): 169-173.
  • 8Svensson J, Brattstrom C, Sawe J, et al. A simple HPLC method for simultaneous determination of mycophenolic acid and mycophenolic acid glucuronide in plasma[J]. Ther Drug Monit, 1999; 21(3): 322-324.
  • 9Allson AC,Eugui EM.Immunosuppressive and other effects of mycophenolic acid and an ester prodrug,mycophenolate mofetil[J].Immunol Rev,1993,136:5-28.
  • 10Sievers TM,Rossi SJ,Ghobrial RM,et al.Mycophenolate mofetil[J].Pharmacotherapy,1997,17(6):1178-1197.

共引文献24

同被引文献126

引证文献12

二级引证文献37

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部